These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 11758578

  • 1. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG.
    Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
    [No Abstract] [Full Text] [Related]

  • 2. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 3. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ.
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 7. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA.
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract] [Full Text] [Related]

  • 10. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D.
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug costs threaten patent protection.
    Cimons M.
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D.
    Food Drug Law J; 1999 Jan; 54(2):241-2. PubMed ID: 11758580
    [No Abstract] [Full Text] [Related]

  • 17. Use patents, carve-outs, and incentives--a new battle in the drug-patent wars.
    Rai A.
    N Engl J Med; 2012 Aug 09; 367(6):491-3. PubMed ID: 22873529
    [No Abstract] [Full Text] [Related]

  • 18. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E.
    Seton Hall Law Rev; 2019 Aug 09; 49(1):53-127. PubMed ID: 30557922
    [No Abstract] [Full Text] [Related]

  • 19. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century.
    Schroeder RG, Papas P.
    Food Drug Law J; 2001 Aug 09; 56(1):19-26. PubMed ID: 11942348
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.